This week’s main blog discussions include … What would you do if you lost a billion dollars? Whilst walking the dog, I’ve been entertained by a fascinating series of podcasts on BBC Sounds called Fool’s Gold. It tells the story of two detectorists – folks who search everywhere using metal detectors – who found gold … Read more
By Thomas Kerr, CFA NASDAQ:CTSO READ THE FULL CTSO RESEARCH REPORT Update on the DrugSorb-ATR Regulatory Process Management reiterated that their De Novo DrugSorb-ATR submission continued to be in interactive review with FDA, that their Medical Device License application to Health Canada was in advanced review, and that they continue to expect regulatory decisions in … Read more
By Thomas Kerr, CFA NASDAQ:MGRM READ THE FULL MGRM RESEARCH REPORT 4th Quarter and Full Year 2024 Financial Results Monogram (NASDAQ:MGRM) reported 4th quarter and full year 2024 financial results on March 12th which were largely in line with our expectations. Research and development expenses for 2024 were $8.8 million compared to $10.6 million in … Read more
By Thomas Kerr, CFA NASDAQ:CTSO READ THE FULL CTSO RESEARCH REPORT On January 3, 2025, CytoSorbents (NASDAQ:CTSO) reported strong preliminary 4th quarter and full year 2024 financial results which exceeded our expectations. 4th quarter product revenue (excluding grant income) is estimated to be in the range of $9.0-$9.2 million, which is approximately 22% to 25% … Read more
This week’s blog discussions include: What does Trump’s victory mean for banks, tech, fintech and the future? Unsurprisingly, after a major election that will influence the Western world, the election of Donald Trump resulted in a flood of PR releases and contacts to tell me how this will influence the economy, Europe and the world. … Read more